Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638983 | 0.84 | CYP1A2 (0.52) | CYP2A6CYP1A2LMNATSHRNR4A2 | |
| SCHEMBL152508 | 0.75 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL67474 | 0.73 | CYP1A2 (0.50) | CYP2A6CYP1A2LMNATSHRATM | |
| SCHEMBL249412 | 0.73 | ALDH1A1 (0.43) | CYP1A2LMNATSHRNR4A2KMT2A | |
| SCHEMBL2333542 | 0.73 | ALDH1A1 (0.43) | CYP1A2LMNATSHRNR4A2KMT2A | |
| SCHEMBL1299258 | 0.73 | TP53 (0.37) | CYP2A6TSHR | |
| SCHEMBL6152174 | 0.71 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL50091 | 0.71 | IDO1 (0.48) | CYP1A2LMNATSHR | |
| SCHEMBL5602251 | 0.71 | CYP1A2 (0.42) | CYP2A6CYP1A2NR4A2KMT2AATM | |
| SCHEMBL3888118 | 0.71 | CYP1A2 (0.31) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 862 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | claimed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-111808045-B | Method for synthesizing chiral seven-element cyclic sulfonamide through organic catalysis | 中国科学院大连化学物理研究所 | 2022-07-08 | — | — | CN | claimed |
| CN-113354515-A | Synthesis method of chiral trans-2-substituted cycloalkanol | 中国科学院大连化学物理研究所 | 2021-09-07 | — | — | CN | claimed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | claimed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | claimed |
| EP-3625223-A1 | PYRIMIDINE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | claimed |
| CN-110621667-A | Pyrimidine derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | claimed |
| WO-2018210992-A1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | claimed |
| US-4435329-A | ANTIHYPERTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | claimed |
| EP-0010347-B1 | NOVEL SUBSTITUTED OMEGA-AROYL(PROPIONYL OR BUTYRYL)-L-PROLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1983-11-09 | — | — | EP | claimed |
| EP-0082340-A1 | Microbicidal triazolyl-ethyl-ethers | CIBA-GEIGY AG (CH) | 1983-06-29 | — | — | EP | claimed |
| US-4374249-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-02-15 | — | — | US | claimed |
| US-4260816-A | HYPOGLYCEMIC, HYPOLIPIDEMIC AGENTS, TREATMENT OF DIABETES | AMERICAN CYANAMID COMPANY (US) | 1981-04-07 | — | — | US | claimed |
| US-4226775-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | claimed |
| EP-0010347-A1 | Novel substituted omega-aroyl(propionyl or butyryl)-L-prolines, pharmaceutical compositions containing them and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-04-30 | — | — | EP | claimed |
| US-4182776-A | Method of treating lipidemia with aryloxyalkylaminobenzoic acids and esters | AMERICAN CYANAMID COMPANY (US) | 1980-01-08 | — | — | US | claimed |
| US-4168385-A | LOWERING OF STEROL AND TRIGLYCERIDE SERUM LEVELS | AMERICAN CYANAMID COMPANY (US) | 1979-09-18 | — | — | US | claimed |
| US-4125729-A | Hypolipemic α-aryloxy para substituted phenyl acetic acid compounds | AMERICAN CYANAMID COMPANY (US) | 1978-11-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | CYP2A6 186/4885CYP1A2 115/4885LMNA 4541/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | CYP2A6 3345/4885CYP1A2 3777/4885LMNA 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.